Adult Dosing

Severe Hypertriglyceridemia

• 2 gm (2 caps) PO bid with food

Note:

• Swallow capsule whole; do not break open, dissolve, crush, or chew capsule

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Adjunct to diet to reduce triglyceride (TG) levels in patients with severe (500 mg/dL) hypertriglyceridemia

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels periodically in patients with hepatic impairment receving icosapent ethyl
• Use cautiously in patients with known hypersensitivity to fish and/or shellfish

Caution: Use cautiously in:

• Nursing mothers

Pregnancy Category:C

Breastfeeding: Omega-3-acid ethyl esters are excreted in human breast milk, however effects of excretion are unknown. Manufacturer advises caution.

• MUSC: Arthralgia
• EENT: Oropharyngeal pain

• Fatty Acids: Ethyl ester of eicosapentaenoic acid (EPA) reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion; increases triglyceride clearance from circulating VLDL particle and beta-oxidation, inhibits acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT), decrease lipogenesis in liver, and increase plasma lipoprotein lipase activity
• Metabolized by liver via beta-oxidation
• Does not undergo renal excretion
• Half life: 89 hours

US Trade Name(s)

• Vascepa

US Availability

Vascepa

• CAPS: 1 gm

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Cardiovascular

Lipid Lowering Agent

omega-3 Acids